Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6625548 | 1.00 | CHRM2 (0.59) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Oxalic Acid SCHEMBL6628862 | 0.92 | CHRM2 (0.52) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL6627286 | 0.91 | CHRM2 (0.60) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL12043252 | 0.91 | CHRM2 (0.60) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Oxalic Acid SCHEMBL6626814 | 0.84 | CHRM2 (0.54) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL9523471 | 0.80 | CHRM2 (0.61) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL6630451 | 0.79 | CHRM2 (0.59) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL6630449 | 0.79 | CHRM2 (0.59) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL14243467 | 0.79 | CHRM2 (0.59) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL12043288 | 0.79 | CHRM2 (0.59) | CHRM2CHRM4CHRM1CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | CHRM2 15/4885CHRM4 17/4885CHRM1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.